Clinical trials located in

Ostrowiec Świętokrzyski

Ostrowiec Świętokrzyski city is located in Poland. Currently, 8 clinical trials are being conducted in this city.

Ostrowiec Świętokrzyski, nestled in the Świętokrzyskie Voivodeship of Poland, boasts a rich industrial heritage, primarily known for its iron industry roots dating back to the 19th century. This city, with a history steeped in the production of steel and heavy machinery, also harbors a vibrant cultural scene. Landmarks like the Church of St. Michael the Archangel and the White Eagle Museum, which showcases local history and art, highlight its diverse historical tapestry. Despite its industrial past, Ostrowiec Świętokrzyski is surrounded by the picturesque landscapes of the Świętokrzyskie Mountains, blending its historical and natural beauty.

  • CT-EU-00057838

    Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    • povorcitinib
    • ICS-LABA
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Studying povorcitinib safety and effects on nonsegmental vitiligo

    This trial studies the effectiveness and safety of povorcitinib for nonsegmental vitiligo. Participants will receive Povorcitinib or a placebo for 52 weeks. The study aims to see if Povorcitinib can significantly improve vitiligo symptoms on the face and body. It’s open to adults with a clinical diagnosis of nonsegmental vitiligo. Safety, side effects, and treatment efficacy are key focuses, aiming to advance vitiligo treatments and care.

    • povorcitinib
  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    • GSK3511294 (Depemokimab)
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.